However, no definitive studies showed which combination therapy between immunotherapy, anti-angiogenic therapy and chemotherapy is the most efficacious strategy in EGFR-mutated NSCLC patients after EGFR-TKIs resistance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.